Laura Chalmers, MD
Pediatric Endocrinology · Tulsa, OKNPI 1710046156
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $126 of the $150 with a category attached, or 83.9%. Neurocrine Biosciences, Inc. accounts for 83.9% of it on its own, with 1 other manufacturer making up the rest.
Across 2 payments — averaging $75.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$126
- Amgen$24
Across 54 payments — averaging $2892.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Neurocrine Biosciences, Inc.$156K
What the payments were for
- Food & beverage$12684%
- Education$2416%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 1 | $126 |
| Amgen | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CRENESSITY$126
How this compares
Too few pediatric endocrinology providers in Oklahomato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 178 | $183,111 |
| GenotropinSomatropin | 50 | $85,147 |
| MounjaroTirzepatide | 53 | $73,366 |
| TrulicityDulaglutide | 68 | $72,482 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 54 | $59,527 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 46 | $48,024 |
| JardianceEmpagliflozin | 45 | $42,759 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 15 | $33,891 |
| Humalog Kwikpen U-100Insulin Lispro | 75 | $21,836 |
| NovologInsulin Aspart | 62 | $18,145 |
| OmnitropeSomatropin | 12 | $15,006 |
| Tresiba Flextouch U-100Insulin Degludec | 30 | $14,802 |
| SynthroidLevothyroxine Sodium | 213 | $14,441 |
| Novolog FlexpenInsulin Aspart | 54 | $13,550 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 109 | $12,509 |
Paid to pharmacies, not to this prescriber.
Other pediatric endocrinology in Tulsa
- Shelly MercerTulsa$1K
- David JelleyTulsa$114
- Steven ChernausekOklahoma City$41K
- Ankur RughaniOklahoma City$20K
- Kenneth CopelandOklahoma City$15K
- Rebecca SchaubOklahoma City$3K
- David SparlingOklahoma City$1K
- Paul DasariOklahoma City$1K
- Minu GeorgeOklahoma City$511
- Maha YousifOklahoma City$309
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.